MARKET

CNCE

CNCE

Concert Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.95
+0.07
+0.89%
After Hours: 7.95 0 0.00% 16:41 12/10 EST
OPEN
7.86
PREV CLOSE
7.88
HIGH
7.99
LOW
7.73
VOLUME
128.90K
TURNOVER
--
52 WEEK HIGH
17.83
52 WEEK LOW
5.36
MARKET CAP
189.54M
P/E (TTM)
-2.3912
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CNCE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CNCE News

  • Concert Pharma launches mid-stage study of CTP-692 in schizophrenia
  • Seeking Alpha - Article.12/02 16:13
  • Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia
  • Business Wire.12/02 12:00
  • Edited Transcript of CNCE earnings conference call or presentation 7-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.11/25 22:57
  • Concert Pharmaceuticals to Present at Upcoming Investor Conferences
  • Business Wire.11/12 12:00

More

Industry

Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
-0.29%

Hot Stocks

Name
Price
%Change

About CNCE

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
More

Webull offers Concert Pharmaceuticals Inc (CNCE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.